Loading...
•
Dec 31, 2024
Mirum Pharmaceuticals Q4 2024 Earnings Report
Mirum Pharmaceuticals reported its fourth quarter and full-year 2024 financial results, highlighting significant growth in product sales and progress in its clinical pipeline.
Key Takeaways
Mirum Pharmaceuticals reported strong financial performance in Q4 2024, with total revenue reaching $99.4 million and a net loss of $23.79 million. The company also provided positive full-year 2025 guidance, expecting continued revenue growth and positive cash flow.
Total net product sales for 2024 reached $336.4 million, exceeding expectations.
The VISTAS study for volixibat in PSC is expected to complete enrollment in the second half of 2025, with topline data anticipated in 2026.
CTEXLI (chenodiol) received US approval for cerebrotendinous xanthomatosis.
The company ended 2024 with $292.8 million in cash, cash equivalents, and investments, indicating a strong financial position.
Mirum Pharmaceuticals
Mirum Pharmaceuticals
Mirum Pharmaceuticals Revenue by Segment
Revenue by Segment
Product Sales, Net Revenue
CapyFin.comLicense and Other Revenue
CapyFin.com Forward Guidance
Mirum Pharmaceuticals expects continued revenue growth in 2025, with global net product sales projected to be between $420 million and $435 million, and anticipates achieving positive cash flow.
Positive Outlook
- Expected continued revenue growth in 2025.
- Anticipated global net product sales of approximately $420 million to $435 million in 2025.
- Expectation of positive cash flow in 2025.
- VISTAS study in primary sclerosing cholangitis (PSC) expected to complete enrollment in second half 2025.
- Expect to initiate Phase 2 study for MRM-3379 in Fragile X Syndrome (FXS) in 2025.
Challenges Ahead
- No specific negative forward guidance was provided in the report.